Clinical Trial Update: Effects of GSK2798745 on Alveolar Barrier Disruption in a Segmental Lipopolysaccharide (LPS) Challenge Model [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating the effect of GSK2798745 on alveolar barrier disruption in an LPS-induced lung injury model in healthy volunteers; study terminated wit…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Healthy Volunteers

Drugs mentioned

• GSK2798745

Snippet

Sponsor: GlaxoSmithKline | Conditions: Healthy Volunteers | Phase 1 | Status: TERMINATED | Results posted: 2020-02-05